Two-year survival with nivolumab in previously treated advanced non–small-cell lung cancer: a real-world pooled analysis of patients from France, Germany, and Canada
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
In: Lung cancer, 157.2022, S. 40-47
- Event
-
Veröffentlichung
- (where)
-
Frankfurt am Main
- (who)
-
Universitätsbibliothek Johann Christian Senckenberg
- (when)
-
2021
- Creator
-
Debieuvre, Didier
Juergens, Rosalyn A.
Asselain, Bernard
Audigier-Valette, Clarisse
Auliac, Jean-Bernard
Barlesi, Fabrice
Benoit, Nicolas
Bombaron, Pierre
Butts, Charles A.
Dixmier, Adrien
Gröschel, Andreas Günter
Gütz, Sylvia
Labbé, Catherine
Moro-Sibilot, Denis
Pérol, Maurice
Raspaud, Christophe
Schumann, Christian
Juarez-Garcia, Ariadna
Lakhdari, Khalid
Pettersson, Filippa
Penrod, John R.
Reynaud, Dorothee
Waldenberger, Daniela
Allan, Victoria
Sebastian, Martin
- DOI
-
10.1016/j.lungcan.2021.04.022
- URN
-
urn:nbn:de:hebis:30:3-630954
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:26 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Debieuvre, Didier
- Juergens, Rosalyn A.
- Asselain, Bernard
- Audigier-Valette, Clarisse
- Auliac, Jean-Bernard
- Barlesi, Fabrice
- Benoit, Nicolas
- Bombaron, Pierre
- Butts, Charles A.
- Dixmier, Adrien
- Gröschel, Andreas Günter
- Gütz, Sylvia
- Labbé, Catherine
- Moro-Sibilot, Denis
- Pérol, Maurice
- Raspaud, Christophe
- Schumann, Christian
- Juarez-Garcia, Ariadna
- Lakhdari, Khalid
- Pettersson, Filippa
- Penrod, John R.
- Reynaud, Dorothee
- Waldenberger, Daniela
- Allan, Victoria
- Sebastian, Martin
- Universitätsbibliothek Johann Christian Senckenberg
Time of origin
- 2021
Other Objects (12)
Cost Effectiveness of Nivolumab in Patients with Advanced, Previously Treated Squamous and Non-squamous Non-small-cell Lung Cancer in England
Role of Crizotinib in previously treated non-small-cell lung cancer
Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab
FDG-PET in the evaluation of response to nivolumab in recurrent non-small-cell lung cancer
Safety of nivolumab monotherapy in five cancer types: pooled analysis of post-marketing surveillance in Japan
Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial
Nivolumab Versus Docetaxel for Previously Treated Advanced Non-Small Cell Lung Cancer in China: A Cost-Effectiveness Analysis
Gefitinib (Iressa, ZD 1839) A Potential Chemotherapy Sensitizer in Previously Chemotherapy Nonresponded Advanced Non-Small-Cell Lung Cancer Patients
Long-term responders to nivolumab in previously treated advanced renal cell carcinoma: a sub-analysis of meet-URO15 study
Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in an open-label phase 1b/2 study
Different Response to Nivolumab in a Patient with Synchronous Double Primary Carcinomas of Hypopharyngeal Cancer and Non-Small-Cell Lung Cancer
Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trials
Cost Effectiveness of Nivolumab in Patients with Advanced, Previously Treated Squamous and Non-squamous Non-small-cell Lung Cancer in England
Role of Crizotinib in previously treated non-small-cell lung cancer
Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab
FDG-PET in the evaluation of response to nivolumab in recurrent non-small-cell lung cancer
Safety of nivolumab monotherapy in five cancer types: pooled analysis of post-marketing surveillance in Japan
Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial
Nivolumab Versus Docetaxel for Previously Treated Advanced Non-Small Cell Lung Cancer in China: A Cost-Effectiveness Analysis
Gefitinib (Iressa, ZD 1839) A Potential Chemotherapy Sensitizer in Previously Chemotherapy Nonresponded Advanced Non-Small-Cell Lung Cancer Patients
Long-term responders to nivolumab in previously treated advanced renal cell carcinoma: a sub-analysis of meet-URO15 study
Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in an open-label phase 1b/2 study
Different Response to Nivolumab in a Patient with Synchronous Double Primary Carcinomas of Hypopharyngeal Cancer and Non-Small-Cell Lung Cancer
Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trials
Cost Effectiveness of Nivolumab in Patients with Advanced, Previously Treated Squamous and Non-squamous Non-small-cell Lung Cancer in England
Role of Crizotinib in previously treated non-small-cell lung cancer
Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab
FDG-PET in the evaluation of response to nivolumab in recurrent non-small-cell lung cancer
Safety of nivolumab monotherapy in five cancer types: pooled analysis of post-marketing surveillance in Japan
Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial
Nivolumab Versus Docetaxel for Previously Treated Advanced Non-Small Cell Lung Cancer in China: A Cost-Effectiveness Analysis
Gefitinib (Iressa, ZD 1839) A Potential Chemotherapy Sensitizer in Previously Chemotherapy Nonresponded Advanced Non-Small-Cell Lung Cancer Patients
Long-term responders to nivolumab in previously treated advanced renal cell carcinoma: a sub-analysis of meet-URO15 study
Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in an open-label phase 1b/2 study
Different Response to Nivolumab in a Patient with Synchronous Double Primary Carcinomas of Hypopharyngeal Cancer and Non-Small-Cell Lung Cancer